Human Dosimetry of the N-Methyl-D-Aspartate Receptor Ligand 11C-GMOM
Human Dosimetry of the N-Methyl-D-Aspartate Receptor Ligand 11C-GMOM
复制标题
DOI：
10.2967/jnumed.116.188250
复制
发表时间：
2017-08-01
影响因子：
9.3
通讯作者：
Lammertsma, Adriaan A.
中科院分区：
文献类型：
--
作者：
van der Aart, Jasper;van der Doef, Thalia F.;Lammertsma, Adriaan A.
甲基胍衍生物C-11-甘氨酰（C-11-标记的N-（2氯-3-硫甲基苯基）-N9-（3-甲氧基苯基）-N9-甲基胍）已成功用于定量人体内N-甲基-D-天冬氨酸（NMDA）受体结合。本研究的目的是估计健康人的C-11-甘精胰岛素辐射剂量。研究方法：注射C-11-甘精胰岛素后，3名女性和2名男性受试者在约77分钟内接受了10次连续全身PET扫描。手动定义7个源器官，按比例缩放至性别特异性参考，并计算停留时间，输入OLINDA/EXM软件。使用可接受的组织加权因子计算有效剂量。结果：放射源器官的平均吸收剂量为脑7.7 μ Gy·MBq ~（21）~脾12.7 μ戈伊·MBq ~（-1）。有效剂量（+/- SD）为4.5 ± 0.5 μ Sv·MBq（-1）。结论：C-11-甘精胰岛素的有效剂量处于其他C-11标记配体的范围下限，允许在单个受试者中进行连续PET扫描。
The methylguanidine derivative C-11-GMOM (C-11-labeled N-(2chloro-3-thiomethylphenyl)-N9-(3-methoxyphenyl)-N9-methylguanidine) has been used successfully to quantify N-methyl-D-aspartate (NMDA) receptor binding in humans. The purpose of the present study was to estimate the C-11-GMOM radiation dose in healthy humans. Methods: After C-11-GMOM injection, 3 female and 2 male subjects underwent 10 consecutive whole-body PET scans in approximately 77 min. Seven source organs were defined manually, scaled to a sex-specific reference, and residence times were calculated for input into OLINDA/EXM software. Accepted tissue-weighting factors were used to calculate the effective dose. Results: The mean absorbed radiation doses in source organs ranged from 7.7 mu Gy.MBq21 in the brain to 12.7 mu Gy.MBq(-1) in the spleen. The effective dose (+/- SD) was 4.5 6 0.5 mu Sv.MBq(-1). Conclusion: The effective dose of C-11-GMOM is at the lower end of the range seen for other C-11-labeled ligands, allowing for serial PET scanning in a single subject.